Clinical Trials Browser

Neoplasm Metastasis

Breast Neoplasms

Solid Tumors

Advanced Cancers

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Solid Tumors

Neoplasms, Prostatic Neoplasms

Lymphoma, Multiple Myeloma, Neoplasms

Lymphoma, Multiple Myeloma, Neoplasms

Breast Neoplasms

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

Glioblastoma, Glioma, Gliosarcoma

Prostatic Neoplasms

Neoplasms, Sarcoma

Endometrial Neoplasms

Neoplasm Metastasis, Recurrence

Neoplasms, Endometrial Neoplasms

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

Bone Neoplasms, Sarcoma

Neoplasm Metastasis, Neoplasms, Recurrence

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Clinical Trials

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

MK-8669-037

MK-8669-064

MK-8669-056

MK-8669-038

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

SUCCEED

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)